Penserra Capital Management LLC Acquires Shares of 150,599 Stoke Therapeutics, Inc. $STOK

Penserra Capital Management LLC bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) in the 3rd quarter, Holdings Channel reports. The fund bought 150,599 shares of the company’s stock, valued at approximately $3,539,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BNP Paribas Financial Markets increased its position in Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after acquiring an additional 1,668 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the last quarter. Strs Ohio acquired a new position in shares of Stoke Therapeutics in the third quarter valued at approximately $150,000. Osaic Holdings Inc. raised its stake in shares of Stoke Therapeutics by 263.3% during the second quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock worth $85,000 after purchasing an additional 5,427 shares during the last quarter. Finally, State of Wyoming purchased a new stake in shares of Stoke Therapeutics during the third quarter worth approximately $184,000.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 3,662 shares of the business’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $31.34, for a total transaction of $114,767.08. Following the sale, the insider directly owned 19,798 shares in the company, valued at approximately $620,469.32. The trade was a 15.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward M. Md Kaye sold 13,430 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $32.27, for a total value of $433,386.10. Following the completion of the sale, the director directly owned 49,124 shares in the company, valued at $1,585,231.48. This trade represents a 21.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 98,774 shares of company stock worth $2,918,365 in the last quarter. Company insiders own 9.50% of the company’s stock.

Stoke Therapeutics Trading Down 4.8%

STOK stock opened at $30.48 on Friday. The company has a market cap of $1.74 billion, a P/E ratio of 45.49 and a beta of 1.10. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $38.69. The company’s 50-day moving average price is $31.43 and its 200 day moving average price is $26.06.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The company had revenue of $10.63 million during the quarter, compared to analysts’ expectations of $6.06 million. On average, equities research analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on STOK shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. HC Wainwright lifted their target price on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a report on Monday, December 15th. UBS Group set a $50.00 price target on shares of Stoke Therapeutics in a research note on Monday, December 15th. Guggenheim began coverage on shares of Stoke Therapeutics in a research report on Thursday. They issued a “buy” rating and a $60.00 price objective for the company. Finally, JPMorgan Chase & Co. lifted their price objective on Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Stoke Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $39.18.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.